proton pump inhibitors (omeprazole)
FDA Approved, EMA Approved
Description
Omeprazole is a proton pump inhibitor that reduces gastric acid secretion by blocking the H+/K+ ATPase enzyme system in gastric parietal cells. It is widely used for the treatment of peptic ulcer disease, including duodenal ulcers, gastroesophageal reflux disease, and Zollinger-Ellison syndrome. While not specifically approved for rare syndromes, it is standard therapy for duodenal ulcer management.
Indications & Therapeutic Use
duodenal ulcer, gastric ulcer, gastroesophageal reflux disease, Zollinger-Ellison syndrome
Linked Diseases:
Global Availability (10 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
proton pump inhibitors (omeprazole)
| Generic Name | proton pump inhibitors (omeprazole) |
| Brands | 1 brand available |
| Active Ingredient | omeprazole |
| Drug Class | duodenal ulcer |
| Manufacturer | AstraZeneca |
| Dosage Forms | Oral capsules 10mg, 20mg, 40mg; IV infusion 40mg |
| Medical Code | A02BC01 |
| Orphan Status | No |
| Cold Chain | Not Required |
| Lead Time | 3 days |
| Reg. Status | FDA Approved, EMA Approved |
| Countries | 10 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations11 Validated Nodes